

Ref. :

Date :

**February 05, 2025**

The National Stock Exchange  
of India Ltd.,  
Exchange Plaza, 5th Floor,  
Bandra-Kurla Complex,  
Mumbai-400 051

BSE Limited  
14th Floor, PJ. Towers,  
Dalal Street,  
Mumbai-400 001

Lotus Eye Hospital and  
Institute Limited,  
SF NO.770/12 Avanashi  
Road, Civil Aerodrome Post,  
Coimbatore,  
Tamil Nadu, India, 641014

Dear Sir/Madam,

SUB: Intimation of acquisition of shares in terms of Regulation 29(1) of SEBI (Substantial Acquisition of shares and takeovers) Regulations, 2011.

We, Vramath Financial Services Private Limited along with PAC are submitting Disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of shares and takeovers) Regulations, 2011 with respect to the acquisition of 20,84,835 (10.02%) Equity shares of Lotus Eye Hospital and Institute Limited, through open-market.

We oblige you to take this on record.

Thanking you,

**For VRAMATH FINANCIAL SERVICES PRIVATE LIMITED**

H. Mugh.  
Jayalakshmi Palaniappan  
Director  
DIN: 03524597



**Disclosures under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011**

**Part-A - Details of the Acquisition**

Name of the Target Company (TC)	Lotus Eye Hospital and Institute Limited		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	<p><b>Acquirer:</b></p> <ol style="list-style-type: none"> <li>1. M/S. Vramath Financial Services Private Limited.</li> </ol> <p><b>Persons Acting in Concert (PAC):</b></p> <ol style="list-style-type: none"> <li>1. M/S. Vramath Investment Consultancy Private Limited.</li> <li>2. PL.M.Palaniappan</li> <li>3. PL. Jayalakshmi</li> <li>4. PL.M.Palaniappan HUF</li> <li>5. PL. Ram Meyyappan</li> </ol>		
Whether the acquirer belongs to Promoter / Promoter group	No		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	<ol style="list-style-type: none"> <li>1. BSE Limited</li> <li>2. National Stock Exchange of India Limited</li> </ol>		
Details of the acquisition / disposals as follows	Number	% w.r.t total share/voting capital wherever applicable (*)	% w.r.t. total diluted share/voting capital of the TC (**)
<b>Before the acquisition under consideration, holding of acquirer along with PACs of:</b>			
a) Shares carrying voting rights	3,58,818	1.73	1.73
b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	NA	NA	NA
c) Voting rights (VR) otherwise than by shares	NA	NA	NA
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying	NA	NA	NA

voting rights in the TC (specify holding in each category)			
e) Total (a+b+c+d)	3,58,818	1.73	1.73
<b>Details of acquisition</b>			
a) Shares carrying voting rights acquired / sold	17,26,017	8.30	8.30
b) VRs acquired otherwise than by equity shares	NA	NA	NA
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired / sold	NA	NA	NA
d) Shares encumbered / invoked/released by the acquire	NA	NA	NA
e) Total (a+b+c+/-d)	17,26,017	8.30	8.30
<b>After the acquisition, holding of acquirer along with PACs of:</b>			
a) Shares carrying voting rights	20,84,835	10.03	10.03
b) Shares encumbered with the acquirer	NA	NA	NA
c) VRs otherwise than by shares	NA	NA	NA
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	NA	NA	NA
e) Total (a+b+c+d)	20,84,835	10.03	10.03

Mode of acquisition / sale (e.g. open market / off-market / public issue / rights issue / preferential allotment / inter-se transfer etc).	Open Market
--	-------------

Date of acquisition / sale of shares / VR or date of receipt of intimation of allotment of shares, whichever is applicable	02/02/2026
Equity shares capital / total voting capital of the TC before the said acquisition / sale	2,07,96,330
Equity shares capital/ total voting capital of the TC after the said acquisition / sale	2,07,96,330
Total diluted share/voting capital of the TC after the said acquisition	2,07,96,330

**Part-B\*\*\***

**Name of the Target Company:** Lotus Eye Hospital and Institute Limited



Signature of the acquirer / Authorised Signatory

Place: Coimbatore

Date: 05/02/2026

**Note:**

(\*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.

(\*\*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(\*\*\*) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.